For example, in advanced lung cancer, driver gene mutations like EGFR and ALK have been shown to be associated with reduced response rates to ICIs and low TMB; therefore, the FDA does not recommend first-line ICI treatment in patients with EGRF or ALK-positive tumors (37, 38). This evidence concerns the gene ALK and lung cancer.